It has been shown to somehow prevent the entry of the virus into the cell. Alongside, it also inhibits signaling pathways of cytokines like IL-2, IL-6 to name a few, mediating the ‘cytokine-storm’. Furthermore, improving lymphocyte count.

JAK Inhibitors and NAK Inhibitors for COVID-19 Treatment (such as Baricitinib) JAK and NAK inhibitors are classified as DMARDs used for the treatment of psoriasis, inflammatory bowel disease (IBD), arthritis and many other conditions. Several hypothesis claim JAK and NAK inhibitors can play a significant role in treatment of COVID-19. According to autopsy findings of COVID-19 patients, hypercoagulation and thrombosis are severe complications of COVID-19 pneumonia. To combat this complication, JAK and NAK inhibitors can be employed. Baricitinib improves leukocyte count and also contributes to prevent entry of virus into cells. Currently, research clinical trials are being conducted to conclude the use of these drugs in the treatment of COVID-19.